Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38353
Title: | Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal beta-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis. | Authors: | Ambrosioni J.;Covino F.E.;Manduca S.;Della Corte A.;De Feo M.;Tripodi M.F.;Baban T.;Kanj S.S.;Sfeir J.;Yasmine M.;Morris A.;Wang A.;Bayer A.S.;Cabell C.H.;Chu V.;Corey G.R.;Durack D.T.;Eykyn S.;Fowler V.G.;Hoen B.;Miro J.M.;Moreillon P.;Sexton D.J.;Olaison L.;Raoult D.;Rubinstein E.;Harris O.;Korman T. ;Kotsanas D.;Jones P.;Reinbott P.;Ryan S.;Garcia P.;Fortes C.Q.;Jones S.B.;Barsic B.;Bukovski S.;Selton-Suty C.;Aissa N.;Doco-Lecompte T.;Delahaye F.;Vandenesch F.;Plesiat P.;Giannitsioti E.;Giamarellou H.;Tarpatzi E.;Durante-Mangoni E.;Iossa D.;Orlando S.;Ursi M.P.;Pafundi P.C.;D' Amico F.;Bernardo M.;Cuccurullo S.;Murdoch D.R.;Dialetto G.;Premru M.M.;Lejko-Zupanc T.;Almela M.;Azqueta M.;Brunet M.;Cervera C.;De Lazzari E.;Falces C.;Fuster D.;Garcia-Gonzalez J.;Gatell J.M.;Ortiz J.;Ninot S.;Pare J.C.;Quintana E.;Ramirez J.;Sandoval E.;Sitges M.;Tolosana J.M.;Vidal B.;Vila J.;Bouza E.;Rodriguez-Creixems M.;Ramallo V.;Bradley S.;Steed L.;Cantey R.;Peterson G.;Stancoven A.;Woods C.;Reller L.B.;Pericas J.M.;Garcia-de-la-Maria C.;Moreno A.;Marco F.;Sharma-Kuinkel B.K.;Carugati M.;Messina J.A.;Park L.;Wray D.;Kanafani Z.A.;Tattevin P.;Munoz P.;Baloch K.;Dixon C.C.;Harding T.;Jones-Richmond M.;Pappas P.;Park L.P.;Redick T.;Stafford J.;Anstrom K.;Athan E.;Chu V.H.;Karchmer A.W. | Monash Health Department(s): | Infectious Diseases and Clinical Microbiology | Institution: | (Athan, Harris) Barwon Health, Australia (Korman) Monash Medical Centre, Australia (Kotsanas) Southern Health, Australia (Jones, Reinbott, Ryan) University of New South Wales, Australia (Fortes) Hospital Universitario Clementino Fraga Filho/UFRJ, Brazil (Garcia, Jones) Hosp. Clinico Pont, Universidad Catolica de Chile, Chile (Barsic, Bukovski) Univ. Hospital for Infectious Diseases, Croatia (Selton-Suty, Aissa, Doco-Lecompte) CHU Nancy-Brabois, France (Delahaye, Vandenesch) Hopital Louis Pradel, France (Tattevin) Pontchaillou University, France (Hoen, Plesiat) University Medical Center of Besancon, France (Giamarellou, Giannitsioti, Tarpatzi) Attikon University General Hospital, Greece (Durante-Mangoni, Iossa, Orlando, Ursi, Pafundi, D' Amico, Bernardo, Cuccurullo, Dialetto, Covino, Manduca, Della Corte, De Feo) Universita della Campania, Italy (Tripodi) University of Salerno, Italy (Baban, Kanafani, Kanj, Sfeir, Yasmine) American University of Beirut Medical Center, Lebanon (Morris) Diagnostic Medlab, New Zealand (Murdoch) University of Otago, New Zealand (Premru, Lejko-Zupanc) Medical Center Ljubljana, Slovenia (Almela, Ambrosioni, Azqueta, Brunet, Cervera, De Lazzari, Falces, Fuster, Garcia-de-la-Maria, Garcia-Gonzalez, Gatell, Marco, Miro, Moreno, Ortiz, Ninot, Pare, Pericas, Quintana, Ramirez, Sandoval, Sitges, Tolosana, Vidal, Vila) Hospital Clinic-IDIBAPS, University of Barcelona, Spain (Bouza, Rodriguez-Creixems, Ramallo) Hospital General Universitario Gregorio Maranon, Spain (Bradley) Ann Arbor VA Medical Center, United States (Wray, Steed, Cantey) Medical University of South Carolina, United States (Peterson, Stancoven) UT-Southwestern Medical Center, United States (Woods, Corey, Reller, Fowler, Chu) Duke University Medical Center, United States (Pericas, Garcia-de-la-Maria, Moreno, Miro) Infectious Diseases Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomediques Pi i Sunyer (IDIBAPS), Barcelona, Spain (Marco) Department of Microbiology, Institute for Global Health, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain (Messina, Park, Sharma-Kuinkel, Carugati, Chu, Fowler) Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, United States (Messina, Chu, Fowler) Duke Clinical Research Institute, Durham, NC, United States (Park) Duke Global Health Institute, Durham, NC, United States (Wray) Infectious Disease Division, Medical University of South Carolina, Charleston, SC, United States (Kanafani) Division of Infectious Diseases, American University of Beirut, Beirut, Lebanon (Durante-Mangoni) Internal Medicine, Department of Clinical and Experimental Medicine, University of Campania 'Luigi Vanvitelli', Italy (Durante-Mangoni) Unit of Infectious and Transplant Medicine, 'V. Monaldi' Hospital, AORN dei Colli, Naples, Italy (Tattevin) Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France | Issue Date: | 11-Aug-2017 | Copyright year: | 2017 | Publisher: | Elsevier B.V. | Place of publication: | United Kingdom | Publication information: | Clinical Microbiology and Infection. 23 (8) (pp 544-549), 2017. Date of Publication: August 2017. | Journal: | Clinical Microbiology and Infection | Abstract: | Objectives Left-sided methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis treated with cloxacillin has a poorer prognosis when the vancomycin minimum inhibitory concentration (MIC) is >=1.5 mg/L. We aimed to validate this using the International Collaboration on Endocarditis cohort and to analyse whether specific genetic characteristics were associated with a high vancomycin MIC (>=1.5 mg/L) phenotype. Methods All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal beta-lactam antibiotics between 2000 and 2006 with available isolates were included. Vancomycin MIC was determined by Etest as either high (>=1.5 mg/L) or low (<1.5 mg/L). Isolates underwent spa typing to infer clonal complexes and multiplex PCR for identifying virulence genes. Univariate analysis was performed to evaluate the association between in-hospital and 1-year mortality, and vancomycin MIC phenotype. Results Sixty-two cases met the inclusion criteria. Vancomycin MIC was low in 28 cases (45%) and high in 34 cases (55%). No significant differences in patient demographic data or characteristics of infection were observed between patients with infective endocarditis due to high and low vancomycin MIC isolates. Isolates with high and low vancomycin MIC had similar distributions of virulence genes and clonal lineages. In-hospital and 1-year mortality did not differ significantly between the two groups (32% (9/28) vs. 27% (9/34), p 0.780; and 43% (12/28) vs. 29% (10/34), p 0.298, for low and high vancomycin MIC respectively). Conclusions In this international cohort of patients with left-sided MSSA endocarditis treated with antistaphylococcal beta-lactams, vancomycin MIC phenotype was not associated with patient demographics, clinical outcome or virulence gene repertoire.Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.cmi.2017.01.017 | Link to associated publication: | Click here for full text options | PubMed URL: | 28159672 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28159672] | ISSN: | 1198-743X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/38353 | Type: | Article | Subjects: | *methicillin susceptible Staphylococcus aureus adult article bacteremia/co [Complication] *bacterial endocarditis/dt [Drug Therapy] bacterial virulence bacterium isolate cerebrovascular accident/co [Complication] clinical outcome cohort analysis embolism/co [Complication] epsilometer test female genetic trait heart failure/co [Complication] human major clinical study male middle aged *minimum inhibitory concentration mortality multiplex polymerase chain reaction phenotype priority journal prospective study *beta lactam antibiotic/ct [Clinical Trial] *beta lactam antibiotic/dt [Drug Therapy] *vancomycin bacteremia / complication *bacterial endocarditis / *drug therapy mortality multiplex polymerase chain reaction phenotype priority journal prospective study *minimum inhibitory concentration middle aged *methicillin susceptible Staphylococcus aureus bacterium isolate male major clinical study bacterial virulence clinical outcome cohort analysis embolism / complication adult Article human heart failure / complication genetic trait female epsilometer test cerebrovascular accident / complication |
Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.